last
year
numer
novel
role
rna
regul
gene
express
discov
addit
tradit
function
conveyor
messag
dna
protein
mani
rna
function
continu
probe
therapeut
applic
earliest
therapeut
nucleic
acid
explor
antisens
oligonucleotid
typic
short
nucleotid
nt
singlestrand
dna
rna
molecul
hybrid
antisens
molecul
target
rna
result
either
degrad
rnase
h
steric
hindranc
mrna
splice
translat
machineri
review
unit
state
food
drug
administr
approv
first
antisens
dna
drug
fomivirsen
isi
pharmaceut
treat
cytomegaloviru
retin
immunocompromis
patient
thu
demonstr
clinic
applic
therapeut
nucleic
acid
achiev
goal
ribozym
aptam
rna
molecul
identifi
also
test
therapeut
potenti
hammerhead
ribozym
class
catalyt
rna
nt
particular
interest
abil
recogn
cleav
specif
rna
sequenc
aptam
highli
structur
rna
nt
high
affin
protein
ligand
make
use
possibl
drug
inhibitor
exampl
transactiv
respons
tar
aptam
encod
bind
viral
transactiv
transcript
protein
tat
overexpress
vitro
tar
render
cell
resist
replic
newest
promis
addit
field
rna
therapeut
aros
discoveri
rna
interfer
rnai
pathway
eventu
nobel
prize
recipi
fire
mello
c
elegan
fire
et
al
note
inject
long
doubl
strand
ds
rna
nt
complementari
specifi
mrna
accompani
effici
elimin
target
transcript
phenotyp
could
reproduc
mammalian
cell
elbashir
et
al
provid
major
breakthrough
show
target
mrna
could
silenc
transfect
cell
chemic
synthes
sirna
design
mimic
nativ
sirna
produc
rnai
system
subsequ
shown
short
hairpin
rna
shrna
mimic
endogen
premirna
could
express
cell
also
yield
effect
target
rna
silenc
studi
usher
new
era
use
sirna
shrna
mammalian
genet
therapeut
approach
rnaibas
therapeut
yet
realiz
consider
potenti
much
work
done
advanc
approach
clinic
rnai
conserv
mechan
posttranscript
gene
silenc
ptg
identifi
multipl
organ
worm
plant
mammal
much
mechan
key
compon
rnai
pathway
appreci
figur
cytoplasm
dicer
rnase
iii
type
enzym
cleav
long
dsrna
nucleotid
nt
sirna
phosphat
group
two
nt
overhang
strand
complementari
target
mrna
call
guid
strand
call
passeng
strand
clue
dicer
recogn
dsrna
substrat
cleavag
site
chosen
lie
within
structur
dicer
protein
usual
contain
helicaseatpas
domain
two
rnaseiiilik
domain
paz
domain
dsrna
bind
domain
size
sirna
produc
predict
distanc
paz
rnaseiii
domain
overhang
common
featur
produc
rnaseiii
activ
sever
posit
charg
residu
connect
domain
thought
facilit
bind
rna
dicer
deliv
sirna
rnainduc
silenc
complex
risc
part
consist
dicer
argonaut
protein
hivtransactiv
respons
rnabind
protein
trbp
argonaut
catalyt
endonucleas
heart
human
risc
bind
sirna
duplex
cleav
remov
passeng
strand
thu
leav
behind
intact
singlestrand
guid
strand
least
complementar
end
tend
serv
guid
furthermor
trbp
bind
thermodynam
stabl
end
sirna
orient
way
help
identifi
guid
strand
degre
complementar
guid
target
mrna
determin
whether
mrna
degrad
exact
match
translat
repress
due
steric
hindranc
partial
homolog
case
exact
homolog
rnase
h
domain
respons
target
mrna
cleavag
endogen
microrna
mirna
natur
substrat
dicer
mammal
review
nucleu
rna
polymeras
ii
pol
ii
transcrib
genomeencod
primari
mirna
primirna
contain
multipl
hairpin
complex
consist
rnase
iii
enzym
drosha
dsrna
bind
protein
cleav
primrna
nt
hairpin
call
premirna
premirna
hairpin
export
cytoplasm
recogn
dicer
cleav
gener
final
mirna
duplex
characterist
two
nt
overhang
novel
dicerindepend
mechan
mirna
process
may
also
exist
sinc
report
cleavag
reli
catalyt
activ
zebrafish
major
mirnaderiv
guid
strand
partial
target
homolog
direct
risc
untransl
region
utr
matur
mrna
result
translat
repress
seed
region
mirna
nt
end
guid
strand
critic
recognit
target
utr
recent
shown
central
nucleotid
also
guid
substrat
select
case
rnai
recogn
critic
regul
virtual
everi
cellular
process
rnai
becom
prefer
method
perform
highli
specif
genet
manipul
function
studi
cell
cultur
rnai
studi
also
greatli
expand
repertoir
possibl
drug
target
treat
metabol
genet
disord
cancer
viral
infect
underli
principl
rnaibas
therapi
trigger
ptg
use
mimic
dicer
substrat
figur
either
chemic
synthes
sirna
viral
express
shrna
synthet
sirna
deliv
dicer
cytosol
varieti
deliveri
approach
shrna
encod
viral
deliveri
vector
must
export
process
endogen
mirna
pathway
studi
song
et
al
demonstr
first
vivo
sirna
applic
diseas
therapi
show
system
deliveri
sirna
duplex
target
fa
mediat
hepat
fibrosi
result
hepatocyteuptak
protect
treat
mice
liver
injuri
fulmin
hepat
mous
model
vivo
studi
diseas
soon
follow
support
efficaci
sirnabas
therapi
review
array
antivir
rnai
therapi
corrobor
anim
model
exampl
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
coxsackieviru
b
sarsassoci
coronaviru
west
nile
viru
herp
simplex
viru
use
topic
applic
rnai
consid
endogen
antivir
mechan
plant
insect
unlik
robust
antivir
pathway
mammalian
somat
cell
howev
evid
limit
antivir
activ
rnai
mammalian
cell
minor
process
hcv
rna
addit
virus
small
rna
infect
report
interestingli
mammalian
virus
replic
mosquito
vector
rnai
primari
antivir
pathway
extrem
low
level
small
rna
identifi
studi
suggest
virus
success
infect
insect
may
evolv
counterstrategi
rnai
hand
virus
replic
insect
vector
hcv
higher
level
short
viral
rna
suggest
absenc
evolutionari
pressur
mammal
express
rnai
antagonist
contrari
idea
rnai
mammalian
antivir
mechan
hcv
fact
util
rnai
support
infect
hcv
replic
infecti
viru
product
inhibit
compon
rnai
pathway
includ
dicer
silenc
sirna
like
relat
downstream
process
effect
loss
cellular
abund
mirna
liver
studi
suggest
play
role
fatti
acid
cholesterol
metabol
hcv
infect
bind
utr
hcv
genom
regul
hcv
translat
replic
unknown
mechan
shown
genotyp
hcv
replicon
replic
inhibit
sequest
infecti
replic
viru
product
inhibit
rna
much
detail
descript
hcv
therapeut
approach
target
describ
special
issu
virus
catherin
jopl
mani
virus
particularli
herpesvirus
coopt
rnai
pathway
express
viral
mirna
modul
either
cellular
viral
gene
express
review
consist
lack
hcv
rnai
antagonist
mani
group
shown
hcv
replic
exquisit
sensit
either
chemic
synthes
sirna
shrna
express
target
hcv
rna
report
sirna
directli
target
hcv
replicon
rna
specif
untransl
region
utr
core
effect
reduc
viral
replic
suggest
sirna
design
region
hcv
genom
vitro
efficaci
sirna
fulli
infecti
hcv
also
shown
major
hcvsirna
complementari
strand
reduct
strand
viral
dsrna
replic
intermedi
observ
plausibl
target
strand
templat
indirectli
lead
decreas
synthesi
strand
although
hcv
mous
model
limit
group
report
rnai
hcv
transgen
express
mice
one
vivo
mous
studi
report
shrna
specif
hcv
utr
effect
diminish
hcv
intern
ribosom
entri
site
ire
driven
luciferas
express
anoth
studi
use
similar
method
mice
report
silenc
transgen
sirna
dsrna
activ
interferon
ifn
pathway
necessari
address
whether
hcvspecif
sirna
could
trigger
ifn
product
kapadia
et
al
demonstr
inhibit
viral
replic
hcv
rnai
vitro
associ
upregul
ifnstimul
gene
fact
hcv
sirna
better
reduc
hcv
rna
level
high
dose
analysi
combin
rnai
ifn
treatment
hcv
replicon
cell
cultur
use
lentivirusdeliv
shrna
perform
result
indic
interfer
gene
silenc
inhibit
hcv
replic
hcvspecif
shrna
enhanc
addit
underscor
possibl
combin
therapi
sirna
ifn
hcv
addit
directli
target
viru
one
import
use
rnai
hcv
therapeut
arena
like
success
identif
novel
drug
target
rnai
gener
approach
use
sirna
shrna
target
cellular
gene
identifi
host
cofactor
hcv
infect
small
molecul
inhibitor
develop
identifi
drug
target
although
host
gene
tradit
overlook
antivir
target
grow
interest
potenti
host
target
minim
viral
resist
possibl
use
broadspectrum
antivir
rnai
use
small
scale
verifi
cofactor
ptb
la
antigen
vapa
import
hcv
replic
mani
group
recent
publish
mediumtohighthroughput
rnai
screen
identifi
hundr
host
factor
util
hcv
identif
cellular
protein
enzymat
function
ideal
develop
novel
small
molecul
inhibitor
andor
therapeut
sirna
two
candid
ubiquitin
specif
peptidas
phosphatidylinositol
iii
alpha
sirna
target
shown
potenti
abil
inhibit
hcv
replic
viru
product
sirna
dramat
reduc
hcv
replic
suggest
critic
viral
replic
cofactor
identif
character
host
cofactor
util
hcv
infect
use
rnai
technolog
signific
advanc
toward
discoveri
much
need
new
therapeut
target
sinc
hcv
major
public
health
burden
current
hcv
therapi
ifn
ribavirin
success
half
treat
patient
mani
altern
therapeut
develop
tradit
small
molecul
approach
inhibit
function
viral
protein
rnaibas
antivir
strategi
number
distinct
advantag
disadvantag
compar
therapi
discuss
one
primari
advantag
sirna
easi
design
synthes
unlik
small
molecul
inhibitor
sever
guid
algorithm
exist
aid
choic
sirna
sirna
must
experiment
test
efficaci
rel
trivial
typic
amen
highthroughput
analysi
also
distinct
target
rna
sirna
versu
protein
small
molecul
inhibitor
yield
promis
inclus
multipl
drug
cocktail
distinct
target
limit
viral
escap
howev
signific
challeng
remain
respect
rnai
therapi
hcv
infect
first
obstacl
rel
eas
viral
resist
sirna
drug
hcv
high
mutat
rate
due
error
prone
viral
rna
polymeras
lead
emerg
drugresist
virus
one
studi
sirnaresist
hcv
replicon
emerg
four
week
hcvsirna
therapi
specif
mutat
target
sequenc
order
minim
risk
drug
resist
multipl
viral
andor
cellular
target
must
consid
case
highli
activ
antiretrovir
therapi
haart
hiv
deliveri
multipl
hcv
sirna
parallel
effect
limit
escap
mutant
altern
sirna
could
also
combin
ifn
treatment
viral
proteas
polymeras
inhibitor
anoth
approach
identifi
highli
conserv
region
hcv
genom
suscept
sirna
sequenc
less
like
mutat
provid
resist
anoth
problem
poor
stabil
sirna
serum
last
minut
due
high
concentr
nucleas
present
blood
howev
nake
sirna
mask
chemic
modif
stabil
maintain
sequenc
specif
review
addit
commonli
use
modif
use
phosphorothio
backbon
linkag
end
sugar
modif
also
offer
protect
nucleas
activ
furthermor
incorpor
acid
arabinonucl
acid
increas
serum
stabil
potenc
sirna
may
deviat
intend
target
alter
express
unintend
mrna
term
offtarget
effect
offtarget
activ
occur
sirna
target
risc
utr
unintend
mrna
activ
map
seed
region
describ
mirna
mirna
translat
repress
occur
exact
pair
seed
region
nt
guid
strand
target
utr
although
partial
seed
match
also
trigger
silenc
given
suffici
basepair
region
mirna
flexibl
make
difficult
predict
potenti
offtarget
activ
synthet
rna
risc
integr
sirna
mirna
pathway
produc
translat
repress
unintend
mrna
contain
seed
region
homolog
howev
chemic
modif
nucleotid
seed
region
greatli
reduc
offtarget
effect
includ
deoxi
lock
nucleic
acid
lna
addit
pool
sirna
could
use
wherein
concentr
individu
sirna
reduc
thu
minim
offtarget
mrna
repress
enhanc
specif
unintend
activ
innat
immun
respons
anoth
complic
sirna
shown
trigger
innat
immun
lead
cytokin
interferon
product
dsrna
nt
activ
protein
kinas
pkr
synthetas
shorter
sirna
duplex
minim
activ
sirna
also
recogn
mammalian
tolllik
receptor
tlr
dsrna
sensor
recogn
ssrna
dsrna
motif
sirna
target
vascular
endotheli
growth
factor
vegf
receptor
clinic
test
treatment
wet
agerel
macular
degener
amd
interestingli
discov
sirna
two
differ
clinic
trial
interact
activ
therebi
indirectli
downregul
vegf
thu
sirna
activ
sequencespecif
unrel
rnai
mechan
sirna
bind
sequencespecif
manner
remedi
case
ad
modif
lastli
guanosin
uracil
rich
region
avoid
sirna
design
may
contribut
sirna
recognit
undesir
offtarget
effect
uniqu
viral
deliveri
shrna
satur
rnai
machineri
overexpress
shrna
found
satur
nuclear
exportin
therebi
inhibit
nuclear
export
activ
cellular
mirna
adenoassoci
viru
attract
deliveri
vehicl
hcv
therapi
due
improv
liver
transduct
effici
aav
vector
studi
grimm
et
al
longterm
overexpress
shrna
vector
deliv
intraven
mice
result
liver
injuri
often
fatal
phenotyp
pinpoint
competit
shrna
host
mirna
limit
cellular
factor
theori
toxic
control
lower
shrna
dosag
either
decreas
amount
viru
strength
shrna
promot
despit
disadvantag
mention
sever
rnaibas
therapi
success
made
clinic
trial
potenti
therapeut
issu
unintend
consequ
toxic
evalu
standard
pharmacokinet
phase
safeti
studi
sirna
drug
promis
treatment
mani
diseas
review
first
gener
therapi
design
treat
wet
amd
major
caus
blind
unit
state
patient
age
first
highli
anticip
sirna
therapi
advanc
phase
iii
clinic
trial
intravitr
inject
bevasiranib
opko
health
design
target
vegf
treatment
wet
amd
show
promis
activ
combin
antivegf
antibodi
ranibizumab
genentech
trial
predict
reach
therapeut
potenti
termin
march
collabor
mercksirna
therapeut
allergan
amd
drug
call
formerli
chemic
modifi
sirna
target
vegf
receptor
also
held
promis
pass
phase
ii
trial
despit
two
setback
formerli
quark
pharmaceut
pfizer
sirna
current
phase
ii
trial
use
amd
also
diabet
macular
degener
use
advanc
approach
calando
pharmaceut
rnai
therapeut
candid
treatment
solid
tumor
consist
transferrinco
cyclodextrin
nanoparticl
contain
sirna
target
subunit
ribonucleotid
reductas
cancer
target
recent
report
show
system
administr
current
phase
trial
specif
inhibit
intend
mrna
transcript
human
unlik
offtarget
effect
report
clinic
rnai
therapi
first
evid
rnai
therapeut
human
inde
work
rnai
mechan
depend
upregul
transferrin
receptor
cancer
cell
also
first
clinic
sirna
therapi
util
receptormedi
deliveri
silenc
therapeut
ag
develop
uniqu
sirnalipoplex
formul
target
protein
kinas
effector
pathway
drug
explor
phase
trial
antiangiogenesi
therapi
advanc
solid
cancer
sirnamedi
treatment
boost
immun
respons
metastat
melanoma
also
phase
duke
univers
studi
patient
inject
autolog
dendrit
cell
transfect
melanoma
tumor
antigen
express
construct
sirna
target
immunoproteosom
presum
enhanc
melanoma
antigen
present
first
antivir
sirna
drug
approv
clinic
trial
target
respiratori
syncyti
viru
rsv
rsv
caus
respiratori
tract
infect
sever
children
alnylam
pharmacuet
target
rsv
nucleocapsid
inhibit
viral
replic
lung
find
phase
ii
trial
involv
healthi
adult
experiment
inocul
rsv
publish
prevent
treatment
modal
incorpor
trial
design
either
modal
viral
load
diminish
patient
treat
compar
placebo
howev
signific
antivir
effect
observ
administ
prophylact
phase
ii
trial
test
efficaci
natur
infect
lung
transplant
patient
complet
phase
iib
begun
benitec
collabor
citi
hope
nation
medic
center
california
publish
phase
clinic
trial
rnai
therapi
june
autolog
cell
hiv
patient
aidsrel
lymphoma
modifi
tripl
combin
vector
consist
shrna
target
tatrev
exon
tar
rna
decoy
target
hammerhead
ribozym
combin
afford
long
term
suppress
hiv
replic
prior
vitro
studi
clinic
result
show
feasibl
well
toler
patient
sustain
express
month
lastli
safeti
therapeut
hcv
target
analyz
phase
clinic
trial
santari
pharma
lnamodifi
phosphorothio
oligonucleotid
publish
effect
silenc
african
green
monkey
produc
prolong
suppress
viremia
without
hcv
resist
chronic
infect
chimpanze
toler
reduct
cholesterol
level
phase
clinic
trial
began
year
compet
antivir
develop
glaxosmithklin
regulu
therapeut
schedul
phase
trial
clinic
studi
pave
way
design
effect
rnai
strategi
patient
major
challeng
progress
hcv
vitro
proof
concept
studi
vivo
therapeut
approach
use
sirna
shrna
especi
challeng
hcv
due
limit
anim
model
greatest
breakthrough
hcv
rna
therapeut
thu
far
sirna
shrna
drug
date
success
treatment
hcv
anim
model
support
approach
far
biggest
hurdl
hcv
sirna
therapi
effici
deliveri
sirna
cytosol
infect
hepatocyt
entail
maxim
uptak
sirna
liver
escap
sirna
endocyt
compart
cytosol
liver
attract
organ
uptak
nucleic
acid
follow
system
deliveri
evidenc
sever
report
show
nake
sirna
readili
taken
liver
mice
use
hydrodynam
tail
vein
inject
deliveri
approach
involv
rapid
larg
volum
inject
amen
use
human
amount
sirna
requir
therapeut
effect
hepat
b
viru
hbv
use
intraven
inject
anim
model
order
magnitud
conceiv
therapeut
dose
peopl
nevertheless
method
import
first
demonstr
sirna
efficaci
hepatocyt
vivo
multipl
approach
taken
improv
uptak
deliveri
liver
outlin
one
approach
improv
specif
organ
deliveri
conjug
sirna
biolog
relev
molecul
strategi
behind
lipophil
modif
sirna
depend
bind
lipoprotein
intern
lowdens
highdens
lipoprotein
ldl
hdl
receptor
highli
express
liver
intraven
inject
cholesterolconjug
sirna
apolipoprotein
b
apob
effect
silenc
transcript
liver
jejunum
mice
result
lower
cholesterol
level
sirna
conjug
bilesalt
deriv
long
chain
fatti
acid
also
found
trigger
rnai
hepatocyt
vivo
vitamin
e
incorpor
lipoprotein
consumpt
includ
ldl
hdl
mind
nishina
et
al
show
sirna
tocsirna
specif
apob
effect
deliv
process
dicer
liver
mice
without
stimul
ifn
product
neg
charg
plasma
membran
circul
nucleas
present
serum
rapid
clearanc
renal
system
imped
uptak
sirna
one
approach
overcom
issu
membran
charg
nucleas
incorpor
sirna
multilay
polyelectrolyt
film
mpf
consist
altern
layer
polyc
polyanion
wherein
sirna
semiprotect
spontan
releas
diffus
cell
uptak
use
method
dimitrova
et
al
show
effect
sustain
inhibit
hcv
replic
cell
cultur
use
hcv
sirna
complex
within
mpf
anoth
approach
use
stabl
nucleic
acid
lipid
particl
snalp
contain
sirna
within
combin
cation
fusogen
lipid
coat
polyethelen
glycol
peg
snalp
success
use
deliv
antihbv
sirna
inhibit
hbv
replic
mous
hepatocyt
deliv
antiapob
sirna
mice
monkey
type
cation
lipidbas
vehicl
develop
base
librari
cation
lipidlik
molecul
call
lipidoid
gener
ad
primari
secondari
amin
alkylacryl
alkylacrylamid
lead
compound
identifi
combin
cholesterol
peg
lipid
effect
encapsul
deliv
sirna
mous
hepatocyt
although
cation
liposom
improv
hepat
deliveri
sirna
uptak
often
observ
organ
also
liposomesirna
base
technolog
face
problem
escap
endosom
intern
endosom
releas
facilit
incorpor
fusogen
peptid
ligand
use
phsensit
nanocomplex
review
uniqu
technolog
call
dynam
polyconjug
dpc
address
issu
cellspecif
target
endosom
escap
dpc
consist
hepatocyt
target
ligand
nacetylgalactosamin
conjug
peg
use
shield
agent
prevent
nonspecif
interact
nanoparticl
endosomolyt
polym
activ
acid
environ
endosom
use
singl
simpl
intraven
inject
antiapob
sirna
carri
dpc
rozema
et
al
report
specif
reduct
apob
mrna
liver
hepatocyt
specif
kupffer
cell
jejunum
mice
thu
demonstr
effect
util
target
ligand
viral
vector
anoth
mean
trigger
rnai
hepatocyt
shrna
clone
viral
vector
control
pol
ii
pol
iii
promot
typic
packag
lentiviru
adenoviru
aav
particl
viral
encod
deliv
shrna
benefit
longterm
express
divid
nondivid
cell
incorpor
target
ligand
direct
viral
vector
specif
cell
target
ligand
incorpor
viral
particl
liverspecif
rna
pol
promot
use
drive
shrna
express
virus
natur
tropism
certain
tissu
use
case
hepatrop
howev
mention
earlier
downsid
viralencod
shrna
rnai
satur
toxic
identif
rnai
mammalian
cell
less
decad
old
howev
field
dramat
alter
fundament
understand
gene
regul
almost
everi
set
clear
enorm
potenti
rnaibas
therapi
yet
unreal
case
hcv
rnai
therapi
next
gener
antivir
emerg
clinic
trial
almost
certainli
classic
proteas
polymeras
small
molecul
inhibitor
use
combin
ifn
ribavirin
nevertheless
clear
addit
therapeut
strategi
involv
novel
target
like
requir
treat
patient
fail
respond
combin
therapi
propos
treat
patient
possibl
rnai
therapeut
may
one
next
gener
drug
help
fill
nich
compel
strength
rnai
therapeut
approach
proper
modif
design
minim
offtarget
effect
maxim
effect
deliveri
sirna
shrna
hepat
cytosol
univers
applic
liver
target
sirna
nucleotid
sequenc
need
chang
order
target
hepatotrop
viru
liver
gene
target
eg
treat
diseas
elev
ldl
cholesterol
thu
issu
effect
deliveri
overcom
trivial
appli
technolog
mani
differ
hepatotrop
diseas
